Lexaria Bioscience Corp. LEXX Archives - Page 38 of 39

ThursdayJul 29, 2021 12:03 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Study Results Indicating DehydraTECH-CBD Lowers Blood Pressure

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released results from its recent human clinical study focused on evaluating DehydraTECh(TM)-processed cannabidiol (“CBD”) for potential application against hypertension. The study, HYPER-H21-1, indicated a rapid, sustained drop in blood pressure with DehydraTECH-CBD as well as excellent tolerability. The partial results will be followed by more complete results after additional BP subset analyses and other data analyses are completed. According to the study’s lead investigator, Dr. Phil Ainslie, the early results appear to be extremely promising as blood pressure was reduced across both male and female volunteers and supported earlier findings…

ThursdayJul 29, 2021 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability

Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses The company envisions building on its recent successes with larger studies of the…

WednesdayJul 28, 2021 10:51 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reached a significant point in its second human clinical study of 2021: HYPER-H21-2. The company announced that dosing has been completed in the study, which was comprised of 16 human volunteers who were pre- or mildly hypertensive; each participant received three separate doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo. The study also included 24-hour continuous monitoring of blood pressure and heart rate, as well as evaluations of central arterial stiffness, physical activity and sleep quality. This key information will be assessed to evaluate the…

TuesdayJul 27, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine

The study indicated enhanced delivery of colchicine using the company’s proprietary DehydraTECH(TM) technology Lexaria collaborates with the National Research Council (“NRC”), Canada’s leading research and technology organization The company has 20 patents granted and over 50 pending patents in over 40 countries around the world The global market for advanced drug delivery systems was valued at $231 billion in 2020 and is expected to grow to $310 billion by 2025 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the tolerability and pharmacokinetic study entitled VIRAL-A20-3 was completed and yielded positive results. The study demonstrated…

MondayJul 26, 2021 3:53 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $3.8M Through Warrant Exercises

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of US$3,817,643 from the exercise of share purchase warrants. According to the update, the company issued the warrants pursuant to its January 2021 public underwritten offering. The shares and warrants issued thereunder were registered pursuant to a Form S-1 Registration Statement (No. 333-250326), as amended, and a Form S-1MEF Registration Statement (No. 333-252031). The warrants were exercised into 580,189 shares of voting common stock of the company, each at an exercise price of US$6.58. The company will utilize all proceeds received from the…

FridayJul 23, 2021 9:00 am

Test Results Boost Lexaria Bioscience Corp. (NASDAQ: LEXX) Potential in Enhancing Antiviral Drugs

Lexaria Bioscience has completed a study conducted by Canada’s National Research Council for the use of its DehydraTECH IP with five drugs known to target the main protease associated with SARS-CoV-2 infection, including remdesivir The SARS-CoV-2 infection is the underlying force behind the COVID-19 pandemic that has killed millions of people during the past year and currently has begun trending toward a rising infection rate again DehydraTECH technology helps drugs gain better bioavailability through quick and effective introduction into patients’ bloodstreams using oral administration as opposed to injections The recent study results demonstrate that DehydraTECH-processed remdesivir, ebastine, bepridil, rupintrivir, and…

ThursdayJul 22, 2021 11:14 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of Antiviral Drug Studies, Strategy Moving Forward

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a summary of its 2021 antiviral drug program so far this year, noting that all objectives in evaluating its proprietary DehydraTECH(TM) drug-delivery platform have been achieved. In addition, the company also discussed next steps. In short, the company stated that it has successfully tested and released summary results on five different compounds from three antiviral drug classes, with results gathered that indicate up to a threefold increase in oral drug delivery into the bloodstream upon animal testing when processed with DehydraTECH. According to the announcement, the company has been able…

WednesdayJul 21, 2021 10:45 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Significantly Enhanced Delivery of Colchicine

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. According to the update, the study demonstrated that DehydraTECH(TM)-enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, benefited from the company’s proprietary formulation and processing, resulting in significantly increased delivery. The study also examined absorption with two other antiviral drugs previously untested by Lexaria; however, the bloodstream delivery findings were unremarkable and further work is required should the company decide to pursue additional testing with…

TuesdayJul 20, 2021 12:33 pm

QualityStocksNewsBreaks – Why Lexaria Bioscience Corp. (NASDAQ: LEXX) Is ‘One to Watch’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is the global innovator behind the patented DehydraTECH(TM) technology. DehydraTECH increases the effectiveness of lipophilic (fat-soluble) drugs and active ingredients and improves the way active pharmaceutical ingredients enter the bloodstream. It speeds up delivery, increases bioavailability, increases brain absorption, improves drug potency, reduces drug administration cost and masks unwanted taste. A recent article reads, “Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats. The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription…

FridayJul 16, 2021 9:30 am

New Patent Expands Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Suite to 20 Granted Worldwide (First in Japan)

Drug delivery platform developer Lexaria Bioscience recently received its 20th patent — granted in Japan for beverages with lipophilic active agents The active agents include non-psychoactive cannabinoids and over-the-counter NSAIDS such as ibuprofen and aspirin that target pain and inflammation Lexaria’s DehydraTECH platform transforms drugs into a powder or liquid form that maintains the drug’s efficacy and allows it to be assimilated by the body more rapidly than normal oral ingestion of pills The company will also announce the latest results from six key R&D projects focusing on concentration levels, tolerability and avoidance of incidental new molecular entities (“NMEs”) soon…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX